---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-029380"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:09:25.637070+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences enters consulting agreement with former CEO Remi Barbier

## Summary
- Consulting agreement effective Sep 13, 2024 for one year, with potential one-year extension.
- Barbier to provide support for scientific research and regulatory approval at $100 per hour.
- Confidentiality, non-disparagement, and cooperation terms apply; severance benefits unchanged.
- Barbier may only communicate with CEO or CFO; no contact with other employees without permission.

## SEC filing metadata
- accession: 0001437749-24-029380
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774924029380/0001437749-24-029380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774924029380/sava20240917_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-029380
- JSON: https://secwatch.observer/filing/0001437749-24-029380.json
- Plain text: https://secwatch.observer/filing/0001437749-24-029380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.